Literature DB >> 19002827

Receptor activator of NF-kappaB ligand induces the fusion of mononuclear preosteoclasts into multinucleated osteoclasts.

J T Woo1, M Kato, M Takami, K Nagai.   

Abstract

The osteoclasts are bone-resorbing multinucleatedcells formed by the fusion of mononuclearpreosteoclasts (pOCs) of hematopoietic origin.Although receptor activator of NF-kappaBligand (RANKL) has been shown to regulate osteoclastdifferentiation and function, its effect on the fusionof pOCs into multinucleated osteoclast-like cells(OCLs) has not been known. Using our fusion assaysystem, that is not contaminated with multinucleatedcells (MNCs) and osteoblastic cells, we determined theeffect of RANKL on the fusion of pOCs into MNCs. WhenpOCs were cultured on the plates, most of pOCs diedand disappeared from the plates within 24 h in theabsence of additives, but pOCs were fused to MNCswithin 6 h in the presence of RANKL. RANKL-inducedMNCs showed typical properties of OCL such astartrate-resistant acid phosphatase (TRAP) activity,actin ring formation, and bone-resorbing activity. Thefusion of pOCs into OCLs induced by osteoblastic cellsor RANKL was inhibited by OPG/OCIF, but that inducedby IL-1beta was not. Both RANKL- andIL-1beta-induced OCL formation from pOCs wasinhibited by ZLLL-H, a peptide inhibitor ofproteasome. These findings indicate that RANKLsupports the survival of pOCs and induces the fusionof pOCs into OCLs and suggest that NF-kappaBactivation is involved in these processes induced byRANKL and IL-1beta.

Entities:  

Year:  2000        PMID: 19002827      PMCID: PMC3466709          DOI: 10.1023/A:1008198120670

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  31 in total

1.  IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation.

Authors:  F Mercurio; H Zhu; B W Murray; A Shevchenko; B L Bennett; J Li; D B Young; M Barbosa; M Mann; A Manning; A Rao
Journal:  Science       Date:  1997-10-31       Impact factor: 47.728

2.  Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Authors:  D L Lacey; E Timms; H L Tan; M J Kelley; C R Dunstan; T Burgess; R Elliott; A Colombero; G Elliott; S Scully; H Hsu; J Sullivan; N Hawkins; E Davy; C Capparelli; A Eli; Y X Qian; S Kaufman; I Sarosi; V Shalhoub; G Senaldi; J Guo; J Delaney; W J Boyle
Journal:  Cell       Date:  1998-04-17       Impact factor: 41.582

3.  Activation of NF-kappaB is involved in the survival of osteoclasts promoted by interleukin-1.

Authors:  E Jimi; I Nakamura; T Ikebe; S Akiyama; N Takahashi; T Suda
Journal:  J Biol Chem       Date:  1998-04-10       Impact factor: 5.157

4.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

Authors:  H Yasuda; N Shima; N Nakagawa; K Yamaguchi; M Kinosaki; S Mochizuki; A Tomoyasu; K Yano; M Goto; A Murakami; E Tsuda; T Morinaga; K Higashio; N Udagawa; N Takahashi; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

5.  Wortmannin, a specific inhibitor of phosphatidylinositol-3 kinase, blocks osteoclastic bone resorption.

Authors:  I Nakamura; N Takahashi; T Sasaki; S Tanaka; N Udagawa; H Murakami; K Kimura; Y Kabuyama; T Kurokawa; T Suda
Journal:  FEBS Lett       Date:  1995-03-13       Impact factor: 4.124

6.  Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase.

Authors:  B G Darnay; V Haridas; J Ni; P A Moore; B B Aggarwal
Journal:  J Biol Chem       Date:  1998-08-07       Impact factor: 5.157

7.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.

Authors:  D M Anderson; E Maraskovsky; W L Billingsley; W C Dougall; M E Tometsko; E R Roux; M C Teepe; R F DuBose; D Cosman; L Galibert
Journal:  Nature       Date:  1997-11-13       Impact factor: 49.962

8.  Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast.

Authors:  T Akatsu; T Murakami; M Nishikawa; K Ono; N Shinomiya; E Tsuda; S Mochizuki; K Yamaguchi; M Kinosaki; K Higashio; M Yamamoto; K Motoyoshi; N Nagata
Journal:  Biochem Biophys Res Commun       Date:  1998-09-18       Impact factor: 3.575

9.  TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor.

Authors:  B R Wong; R Josien; S Y Lee; B Sauter; H L Li; R M Steinman; Y Choi
Journal:  J Exp Med       Date:  1997-12-15       Impact factor: 14.307

10.  TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts.

Authors:  K Fuller; B Wong; S Fox; Y Choi; T J Chambers
Journal:  J Exp Med       Date:  1998-09-07       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.